Hyper-CVAD + epratuzumab as a salvage regimen for younger patients with relapsed/refractory CD22-positive precursor B-cell acute lymphocytic leukemia.
Chevallier P, Chantepie S, Huguet F, Raffoux E, Thomas X, Leguay T, Marchand T, Isnard F, Charbonnier A, Maury S, Gallego-Hernanz MP, Robillard N, Guillaume T, Peterlin P, Garnier A, Rialland F, Le Houerou C, Goldenberg DM, Wegener WA, Béné MC, Dombret H.
Chevallier P, et al. Among authors: robillard n.
Haematologica. 2017 May;102(5):e184-e186. doi: 10.3324/haematol.2016.159905. Epub 2017 Feb 2.
Haematologica. 2017.
PMID: 28154086
Free PMC article.
No abstract available.